What You're Missing Without CGMs: Diabetes Care
- Abigail Hahm
- Mar 24
- 4 min read
Sugar, a familiar indulgence, fulfils our cravings and sweetens our daily lives. But its unassuming nature masks a serious risk: diabetes.
Type 2 diabetes, once primarily associated with older adults, is now emerging in populations where it was previously uncommon. And with the CDC reporting a staggering 38% of US adults have prediabetes, a significant population is at risk. About 12% of the US population currently has diabetes, with most cases occurring in adults over 65 nationwide. But type 2 diabetes has increased in adolescents and youth as well, with the incidence rate predicted to increase to 70% in kids and teens by 2060.
In a significant leap for diabetes management, biotech innovation has ushered in the era of continuous glucose monitors (CGMs). These Bluetooth-enabled devices provide real-time blood sugar tracking, empowering individuals to proactively monitor spikes, dips, and critical patterns, effectively taking control of their condition.
The questions then arise for those undiagnosed, or without diabetes:
If undiagnosed, should a CGM be used to monitor blood sugar levels?
Is this beneficial to use a CGM to track glucose levels if the condition isn’t suspected?
Does blood sugar need to be meticulously monitored?
Dexcom, a biosensor technology company, helps manage glucose levels through CGMs. The company is revolutionizing the biosensor industry for diabetes management, aiming to empower individuals to take control of their health. They aim to enhance continuous glucose monitors (CGMs) and raise awareness about blood sugar levels. Notably, their biosensors offer unique 15-day data access.
Recently, Dexcom released the results of a survey revealing that although medication plays a role in managing type 2 diabetes, technology (access to CGMs) and education surrounding the condition can prospectively impact the rate of type 2 diabetes more positively and effectively. An impressive 93% of CGM users reported significant benefits. For type 1 diabetes patients, Dexcom enhances care by integrating CGMs with insulin delivery systems, boosting regulation and confidence in management.
Not only is this significant in diabetes care but also highlights the worldwide prevalence of Type 2 diabetes in regions like Europe, the Middle East, and North Africa where a majority of individuals face this challenge. Expanding the inclusion of diverse populations with diabetes enables companies like Dexcom to strive toward a future where the accessibility and management of biosensing devices spark an international transformation in diabetes care.
To stem the tide of diabetes and its related illnesses, a public health imperative exists: widespread awareness of blood sugar's impact. The stark reality of sugar's consequences, often hidden, can be illuminated by innovative devices that provide real-time data. This visualization empowers individuals to make informed choices, potentially mitigating long-term health risks. The future of diabetes management may lie not in medication alone, but in accessible knowledge and transformative technologies like these.
To learn more about diabetes management, read this piece.
Read more about the impact of federal research funding cuts on the future of medicine and learn about the most anticipated drug launches of 2025.
Further Reading:
If you liked this article:
Share this article with your network on LinkedIn with your thoughts or perspectives. Make sure to tag us @HealthcareInsights to join the conversation.
Subscribe to our free newsletter, HealthcareIn Quicktakes. You'll never miss an article, and will get access to exclusive reports.
Check out our library of articles and reports on biotech, healthcare, policy, and business.
Who We Are: At Healthcare Insights, we're covering the transformation of healthcare and bringing our readers the most pertinent takes on key issues in medicine, biotech, healthcare policy, and business. Our Spotlight Series ✦ features thoughts from the most influential figures in healthcare, including Nobel Prize-winning scientists shaping tomorrow's treatments and business leaders bringing new therapies to market. We strive to publish coverage that is authentic, impartial, and independent of any financial or political motive. For more information regarding our editorial standards, read our statement. If you'd like to contact the Editor, use this form to get in touch.
If you'd like to stay in the loop, make sure to subscribe to our free newsletter, HealthcareIn Quicktakes, and follow us @healthcareinsightsny across our social channels, including LinkedIn.
©️ Copyright 2025 Healthcare Insights
All Rights Reserved
Legal Disclaimer:
The information provided in this article has been collected from various academic publications, industry reports/analyses, regulatory guidelines, media coverage, and legal analyses. The information provided is for general information purposes only and should not be construed for medical, legal, financial, or professional advice. Readers are advised to seek independent professional guidance where relevant. While we strive to ensure the accuracy and timeliness of our coverage, we claim no liability, representations, or warranties of any kind about the completeness, suitability, accuracy, reliability, authorship, or availability of this article and all pertaining data within this article. Neither the author nor the publication will assume liability for any loss or damage arising from the use of the information provided in the article. The information within this article may be outdated or inaccurate over time, and neither the author nor the publication are obligated to update or revise such information. We reserve the right to modify, remove, or substantially edit the article, including the disclaimer, at any time.
Comments